Efficacy and safety of switching from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension

Trial Profile

Efficacy and safety of switching from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Macitentan (Primary) ; Sildenafil
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2017 New trial record
    • 08 Apr 2017 Primary endpoint of prevalence of patients in WHO functional class III/IV after drug switch has been met, according to results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 08 Apr 2017 Results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top